All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
LL-37 (Cathelicidin Antimicrobial Peptide)
For educational and research purposes only. Not medical advice.
LL-37 is the only human cathelicidin with direct antimicrobial, immunomodulatory, and wound healing properties. Emerging as a treatment for biofilm-associated chronic infections. Clinical trials ongoing for wound healing and UTI prevention.
Best Time
Morning
Method
subcutaneous
Frequency
Daily during acute phase
Half-life
~4-6 hours
Cycle Length
2-4 weeks for acute, longer for chronic
Storage
Refrigerate at 2-8°C.
Published Dosing Ranges
Create an account to access peptide research data.
Contraindications
Create an account to access peptide research data.
BPC-157's tissue repair and cytoprotection combined with LL-37's antimicrobial and wound-healing properties. Theoretical synergy for injury recovery where infection risk is present.
The Journal of pediatrics 275 :114249 · 2024-12-01
Journal of the European Academy of Dermatology and Venereology : JEADV 38 (9) :1760-1768 · 2024-09-01
The journals of gerontology. Series A, Biological sciences and medical sciences 79 (6) · 2024-06-01
Biomolecules 12 (10) · 2022-10-14
Proceedings of the National Academy of Sciences of the United States of America 121 (6) :e2300644120 · 2024-02-06
Mechanism of Action
Human cathelicidin antimicrobial peptide that disrupts bacterial/fungal membranes, neutralizes endotoxins (LPS), modulates immune response, and promotes wound healing. Part of innate immunity.
Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.